Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 19,109 Shares of Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) insider Terrie Curran sold 19,109 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total transaction of $125,928.31. Following the sale, the insider now directly owns 360,465 shares in the company, valued at $2,375,464.35. This represents a 5.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Phathom Pharmaceuticals Price Performance

PHAT opened at $7.17 on Friday. The company’s 50 day simple moving average is $8.08 and its 200-day simple moving average is $12.53. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.57) by $0.25. The firm had revenue of $16.35 million during the quarter, compared to the consensus estimate of $12.54 million. During the same quarter in the previous year, the business posted ($0.76) earnings per share. On average, equities analysts anticipate that Phathom Pharmaceuticals, Inc. will post -4.74 EPS for the current fiscal year.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in PHAT. Huntington National Bank raised its holdings in Phathom Pharmaceuticals by 62.2% during the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after purchasing an additional 564 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Phathom Pharmaceuticals by 41.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after buying an additional 722 shares during the period. US Bancorp DE raised its stake in shares of Phathom Pharmaceuticals by 28.6% during the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock worth $95,000 after buying an additional 1,166 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Phathom Pharmaceuticals by 10.6% in the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock valued at $144,000 after buying an additional 1,339 shares during the period. Finally, Quest Partners LLC bought a new position in Phathom Pharmaceuticals in the third quarter valued at approximately $197,000. Institutional investors own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on PHAT shares. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, January 10th.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.